337 related articles for article (PubMed ID: 33032013)
1. COVID-19-related encephalopathy presenting with aphasia resolving following tocilizumab treatment.
Muccioli L; Pensato U; Cani I; Guerra L; Provini F; Bordin G; Riccioli LA; Lodi R; Tinuper P; Bisulli F
J Neuroimmunol; 2020 Dec; 349():577400. PubMed ID: 33032013
[TBL] [Abstract][Full Text] [Related]
2. Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation.
Janssen MTHF; Ramiro S; Landewé RBM; Magro-Checa C; Mostard RLM
Ann Rheum Dis; 2021 Oct; 80(10):1362-1363. PubMed ID: 33958327
[No Abstract] [Full Text] [Related]
3. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab prescribing criteria for COVID-19 patients.
Al-Qaaneh AM; Al-Ghamdi FH
Hum Vaccin Immunother; 2021 Apr; 17(4):1128. PubMed ID: 33079613
[No Abstract] [Full Text] [Related]
5. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D
J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382
[TBL] [Abstract][Full Text] [Related]
6. Is IL-6 a key cytokine target for therapy in COVID-19?
Jones SA; Hunter CA
Nat Rev Immunol; 2021 Jun; 21(6):337-339. PubMed ID: 33850327
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.
Syam AF; Pitoyo CW; Suhendro S; Zulkarnain B; Indrasari ND; Aditianingsih D; Irawan C; Susilo A; Rumende CM; Wijaya IP; Ibrahim F; Rasmin M; Alwi I; Makmun D
Acta Med Indones; 2021 Apr; 53(2):194-201. PubMed ID: 34251348
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients.
Borku Uysal B; Ikitimur H; Yavuzer S; Ikitimur B; Uysal H; Islamoglu MS; Ozcan E; Aktepe E; Yavuzer H; Cengiz M
J Med Virol; 2020 Nov; 92(11):2648-2656. PubMed ID: 32484930
[TBL] [Abstract][Full Text] [Related]
9. A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.
Khiali S; Khani E; Entezari-Maleki T
J Clin Pharmacol; 2020 Sep; 60(9):1131-1146. PubMed ID: 32557541
[TBL] [Abstract][Full Text] [Related]
10. Persistent intrathecal interleukin-8 production in a patient with SARS-CoV-2-related encephalopathy presenting aphasia: a case report.
Kudo T; Hayashi Y; Kunieda K; Yoshikura N; Kimura A; Otsuki M; Shimohata T
BMC Neurol; 2021 Nov; 21(1):426. PubMed ID: 34727881
[TBL] [Abstract][Full Text] [Related]
11. The shortcomings of tocilizumab in COVID-19.
Tirupathi R; Bharathidasan K; Areti S; Kaur J; Salim S; Al-Tawfiq JA
Infez Med; 2020 Dec; 28(4):465-468. PubMed ID: 33257619
[TBL] [Abstract][Full Text] [Related]
12. Encephalopathy in COVID-19 Presenting With Acute Aphasia Mimicking Stroke.
Pensato U; Muccioli L; Pasini E; Tappatà M; Ferri L; Volpi L; Licchetta L; Battaglia S; Rossini G; Bon I; Re MC; Cirillo L; Simonetti L; Gramegna LL; Michelucci R; Cortelli P; Zini A; Bisulli F
Front Neurol; 2020; 11():587226. PubMed ID: 33193051
[No Abstract] [Full Text] [Related]
13. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
[TBL] [Abstract][Full Text] [Related]
14. Late onset infectious complications and safety of tocilizumab in the management of COVID-19.
Pettit NN; Nguyen CT; Mutlu GM; Wu D; Kimmig L; Pitrak D; Pursell K
J Med Virol; 2021 Mar; 93(3):1459-1464. PubMed ID: 32790075
[TBL] [Abstract][Full Text] [Related]
15. Encephalopathy and encephalitis during acute SARS-CoV-2 infection. Spanish Society of Neurology COVID-19 Registry.
Abenza Abildúa MJ; Atienza S; Carvalho Monteiro G; Erro Aguirre ME; Imaz Aguayo L; Freire Álvarez E; García-Azorín D; Gil-Olarte Montesinos I; Lara Lezama LB; Navarro Pérez MP; Pérez Sánchez JR; Romero Delgado F; Serrano Serrano B; Villarreal Vitorica E; Ezpeleta Echávarri D
Neurologia (Engl Ed); 2021 Mar; 36(2):127-134. PubMed ID: 33549369
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
Ranger A; Haji R; Kaczmarski R; Danga A
Br J Haematol; 2020 Aug; 190(3):e128-e130. PubMed ID: 32480422
[No Abstract] [Full Text] [Related]
17. Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series.
Nakamura H; Miyagi K; Otsuki M; Higure Y; Nishiyama N; Kinjo T; Nakamatsu M; Haranaga S; Tateyama M; Fujita J
Respir Investig; 2020 Nov; 58(6):510-512. PubMed ID: 33067149
[No Abstract] [Full Text] [Related]
18. Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.
Corominas H; Castellví I; Pomar V; Antonijoan R; Mur I; Matas L; Gich I; de Benito N; Laiz A; Castillo D; Villamarin L; Filella D; Millán AM; Quijada MÁ; Puig M; Casademont J; Domingo P
Clin Immunol; 2021 Feb; 223():108631. PubMed ID: 33189888
[TBL] [Abstract][Full Text] [Related]
19. Experience of using tocilizumab for treatment in Indonesian patients with severe COVID-19.
Widysanto A; Kurniawan A; Lugito NPH; Yuniarti M; Gunawan C; Angela ; Wiryanto J; Levinna ; Pradhana TM
Cytokine; 2021 Feb; 138():155393. PubMed ID: 33333393
[TBL] [Abstract][Full Text] [Related]
20. Cytokine release syndrome-associated encephalopathy in patients with COVID-19.
Perrin P; Collongues N; Baloglu S; Bedo D; Bassand X; Lavaux T; Gautier-Vargas G; Keller N; Kremer S; Fafi-Kremer S; Moulin B; Benotmane I; Caillard S
Eur J Neurol; 2021 Jan; 28(1):248-258. PubMed ID: 32853434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
